Ling-Wei Chen1,2, Ssu-Yuan Chen3,4, Hsao-Hsun Hsu5, Yen-Wen Wu6, Yu-Mei Lai5, Meng-Yueh Chien1. 1. School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University. 2. Department of Rehabilitation, Central Clinics and Hospital, Taipei. 3. Department of Rehabilitation, Fu-Jen Catholic University Hospital, New Taipei City. 4. Department of Physical Medicine and Rehabilitation. 5. Department of Surgery, National Taiwan University Hospital, Taipei. 6. Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease with a high mortality rate that can be divided into different groups according to etiology and prognosis. Few studies have investigated differences in the exercise capacity and quality of life (QOL) among the different groups of PAH patients. Therefore, we aimed to (1) compare the hemodynamic exercise responses between patients with idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with other diseases (APAH), and (2) determine the factors associated with exercise capacity in patients with PAH. METHODS: Six patients diagnosed with IPAH and eight with APAH [congenital heart disease (CHD)-dominant PAH] were included in this study. The main outcome measures included body composition, exercise capacity, hemodynamic measurements, physical activity levels, fatigue severity, and QOL. RESULTS: The CHD-dominant PAH group had a significantly lower predicted peak oxygen consumption (VO2pred %), pressure of end-tidal carbon dioxide at the peak and at anaerobic threshold (PETCO2peak and PETCO2@AT), and significantly elevated ventilatory equivalent (VE/VCO2slope and VE/VCO2@AT) compared with the IPAH group. Multiple regression analysis indicated that PETCO2@AT was significantly associated with either VO2peak (β = 0.805, adjusted R2 = 0.619, p = 0.001) or 6-minute walk distance (β = 0.816, adjusted R2 = 0.638, p < 0.001). CONCLUSIONS: Patients with CHD-dominant PAH had poor exercise capacity and exercise responses compared to those with IPAH. Evaluating exercise capacity and the patient response to exercise using cardiopulmonary exercise testing is increasingly important in view of the etiology of PAH.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease with a high mortality rate that can be divided into different groups according to etiology and prognosis. Few studies have investigated differences in the exercise capacity and quality of life (QOL) among the different groups of PAH patients. Therefore, we aimed to (1) compare the hemodynamic exercise responses between patients with idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with other diseases (APAH), and (2) determine the factors associated with exercise capacity in patients with PAH. METHODS: Six patients diagnosed with IPAH and eight with APAH [congenital heart disease (CHD)-dominant PAH] were included in this study. The main outcome measures included body composition, exercise capacity, hemodynamic measurements, physical activity levels, fatigue severity, and QOL. RESULTS: The CHD-dominant PAH group had a significantly lower predicted peak oxygen consumption (VO2pred %), pressure of end-tidal carbon dioxide at the peak and at anaerobic threshold (PETCO2peak and PETCO2@AT), and significantly elevated ventilatory equivalent (VE/VCO2slope and VE/VCO2@AT) compared with the IPAH group. Multiple regression analysis indicated that PETCO2@AT was significantly associated with either VO2peak (β = 0.805, adjusted R2 = 0.619, p = 0.001) or 6-minute walk distance (β = 0.816, adjusted R2 = 0.638, p < 0.001). CONCLUSIONS: Patients with CHD-dominant PAH had poor exercise capacity and exercise responses compared to those with IPAH. Evaluating exercise capacity and the patient response to exercise using cardiopulmonary exercise testing is increasingly important in view of the etiology of PAH.
Entities:
Keywords:
Exercise capacity; Pulmonary arterial hypertension; Pulmonary hypertension; Quality of life
Authors: M L Pollock; B A Franklin; G J Balady; B L Chaitman; J L Fleg; B Fletcher; M Limacher; I L Piña; R A Stein; M Williams; T Bazzarre Journal: Circulation Date: 2000-02-22 Impact factor: 29.690
Authors: Ross Arena; Carl J Lavie; Richard V Milani; Jonathan Myers; Marco Guazzi Journal: J Heart Lung Transplant Date: 2009-12-06 Impact factor: 10.247
Authors: Chris Garvey; Madeline Paternostro Bayles; Larry F Hamm; Kylie Hill; Anne Holland; Trina M Limberg; Martijn A Spruit Journal: J Cardiopulm Rehabil Prev Date: 2016 Mar-Apr Impact factor: 2.081